Selected Publications
Kelley Weinfurtner, David Tischfield, George McClung, Jennifer Crainic, John Gordan, Jing Jiao, Emma E. Furth, Wuyan Li, Erena Tuzneen Supan, Gregory J. Nadolski, Stephen J. Hunt, David E. Kaplan, Terence P.F. Gade: Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts JHep Reports : 2024.
Habibollahi P, Gurevich A, Hui JZ, Weinfurtner K, McClung G, Adler J, Soulen MC, Kaplan DE, Nadolski GJ, Hunt SJ, Tsourkas A, and Gade TP: Integrated imaging probe and bispecific antibody development enables in vivo targeting of glypican-3-expressiong hepatocellular carcinoma. Mol Cancer Ther : 2024.
Willis E, Verrelle J, Secreto A, Cole S, McClung G, Weinfurtner K, Gade TP, Radaelli E: Diagnostic Challenge in Veterinary Pathology: Otitis Media in a Humanized NOG-EXL Mouse Vet Pathol : 2024.
Wong JC, Weinfurtner KM, Westover T, Kim J, Lebish EJ, Alzamora Mdel, Walsh M, Abdelhamed S, Ma J, Klco JM, Shannon K.: 5G2 mutant mice model loss of commonly deleted segment of chromosome 7q22 in myeloid malignancies. Leukemia 38 (5): 1182-1186,2024.
Nicole Ferrante, Rebecca Hubbard, Kelley Weinfurtner, Anya I Mezina, Craig Newcomb, Emma E Furth, Debika Bhattacharya, Basile Njel, Tamar H Taddei, Amit G Singal, Maarouf Hoteit, Lesley S Park, David E Kaplan, Vincent Lo Re: Development and validation of case-finding algorithms to identify cholangiocarcinoma and its subtypes in Veterans Health Administration data Digestive Disease Week : 2024.
Quynh-Anh L Dang, Kelley Weinfurtner, Gregory J Nadolski, Stephen J Hunt, Terence P Gade: Prolonged Treatment Response With Radioembolization Compared to Chemoembolization in Early Stage Hepatocellular Carcinoma Patients Ineligible for Curative Therapy SIR Annual Meeting : 2024.
Weinfurtner K, Kurian M, Ackerman D, Woodard A, Li W, Crainic J, Soulen MC, Dagli M, Shamimi-Noori S, Mondschein J, Sudheendra D, Stavropoulos SW, Reddy S, Khaddash T, Further EE, Siegelman ES, Hunt SJ, Nadolski GJ, Kaplan DE, Gade TPF: Activating B-catenin pathway mutations predict favorable outcomes after transarterial chemoembolization in unresectable hepatocellular carcinoma ILCA Annual Meeting : 2023.
Weinfurtner K, Kurian M, Ackerman D, Woodard A, Li W, Crainic J, Soulen MC, Dagli M, Shamimi-Noori S, Mondschein J, Sudheendra D, Stavropoulos SW, Reddy S, Khaddash T, Further EE, Siegelman ES, Hunt SJ, Nadolski GJ, Kaplan DE, Gade TPF: B-catenin pathway mutations predict favorable outcome after transarterial chemoembolization in unresectable hepatocellular carcinoma AASLD Liver Meeting : 2022.
Kurian M, Weinfurtner K, Ackerman D, Woodard, A, Li W, Soulen MC, Dagli M, Shamimi-Noori S, Mondschein J, Sudheendra D, Stavropoulos SW, Reddy S, Redmond J, Khaddash T, Jahla D, Siegelman ES, Furth EF, Hunt SJ, Nadolski GJ, Kaplan D, Gade TPF.: Response to transarterial chemoembolization varies by genetic subtype in intermediate and advanced hepatocellular carcinoma. SIR Annual Meeting : 2022.
Weinfurtner K, Crainic J, Li W, Ackerman D, Hunt SJ, Nadolski GJ, Kaplan DE, and Gade TPF.: GM-CSF and IL-3 expression increases immune engraftment and tumor infiltration in a humanized patient-derived xenograft model of hepatocellular carcinoma. AASLD Liver Meeting : 2021.
Academic Contact Information
421 Curie Blvd, 910 BRB II/III
Philadelphia,
PA
19104
Patient appointments: 800-789-7366